All notes

3 min readInvestment focus

Health tech seed and pre-seed investment at Variance Ventures

Variance Ventures’ health tech focus, including diagnostics, devices, care delivery and connecting software, with guidance for an early pitch.

By Variance Ventures

Variance Ventures considers pre-seed and seed companies in health technology. Our published focus includes diagnostics, care delivery, medical devices, and the software connecting them. We invest primarily in the United States and consider opportunities globally, with typical initial checks around $50,000 and flexibility on size.

An early health tech pitch needs to connect the product to the setting where it will operate. Who uses it? Who pays? What must happen before a customer can deploy it? Those questions help explain whether a technical advance can become a business within the constraints of healthcare.

Start with a real workflow

Health tech covers several different markets. A diagnostic system, a clinical device, an administrative software product, and a care delivery business should not be evaluated as though they have identical development or commercial paths.

Begin with a specific setting and problem. An illustrative software company might help a clinic coordinate follow-up tasks. Its first pitch should explain how those tasks move between people today, where information gets lost, and which part of that process the product changes. It should also explain the work that remains manual.

For a device or diagnostic, describe the intended use and what has actually been demonstrated. Early engineering performance, usability observations, and clinical evidence answer different questions. Keeping those categories separate makes a technical story easier to assess.

Identify the buyer as well as the user

In healthcare, the person who experiences a problem may have little control over the purchasing decision. Map the user, internal champion, budget owner, and any organization that ultimately funds the service.

A clinician’s enthusiasm can support further investigation without establishing a purchasing commitment. Similarly, a signed pilot can demonstrate willingness to test a product without proving that a larger deployment will be funded.

Tell us what the commercial evidence represents. If an organization has agreed to evaluate the product, explain the evaluation scope, decision criteria, and next purchasing step. If a payment model depends on reimbursement, identify that dependency and the work still needed to establish a viable route. Avoid treating a possible payment mechanism as settled revenue.

Show the path into an operating environment

A demonstration in a controlled environment may omit the hardest deployment work. Explain integrations, implementation effort, training, customer support, and how users handle errors or incomplete information.

Where sensitive information is involved, describe the data the product needs and the controls relevant to the proposed deployment. If the product has clinical functions, explain the intended oversight and the specialist work needed to assess regulatory and evidence requirements. A general claim that the company is “compliant” gives investors less information than a specific account of completed reviews and remaining obligations.

These questions are part of assessing the business, rather than a universal checklist that every health tech product must satisfy in the same way.

Make the next financing milestone concrete

At pre-seed, the next useful evidence might be a working integration, a feasible implementation plan, or a pilot with clear success criteria. At seed, the questions may shift toward repeat deployment, paid expansion, and the cost of delivering the service. The stage label by itself does not tell an investor which risks have been resolved.

Our guide to pilots and commercial evidence walks through the difference between activity and a meaningful buying signal. Use the funding plan to show what changes by the end of the round, who will deliver it, and how the company will respond if a customer decision takes longer than expected.

Put the round together around the business

Some companies need investors with experience in a specific clinical or regulatory setting; others need software deployment expertise or care operations knowledge. Our health tech investor guide offers a starting shortlist with sources and distinctions between firms.

A typical Variance check is one possible contribution to a round. The small-check investor guide discusses how those contributions fit alongside other capital. You can also compare health tech with our six-sector investment focus, particularly where a company crosses into AI, software, or biotechnology.

If the focus fits, send us your pitch. Explain the problem, architecture, team, evidence to date, and capital requirements, including the specific use case and the next step from product demonstration to funded adoption.